Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + envafolimab for advanced or unresectable soft tissue sarcoma after immunotherapy failure
ChiCTR2300077282Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and envafolimab in soft tissue sarcoma (STS), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Objective response rate. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
tucidinostatenvafolimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2300077282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077282.